ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 141,46
-0,67%
Dow Jones
39 872,99
0,17%
DAX
18 726,76
-0,21%
Brent Oil
82,17
-0,33%
Bitcoin
69 973,26
-0,23%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Carisma Therapeutics Inc (CARM)

  7. Carisma Therapeutics Inc (CARM) Actualités

CARM Carisma Therapeutics Inc

1,42
0,01 (0,71%)
22 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Carisma Therapeutics Inc CARM NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,01 0,71% 1,42 00:09:06
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,39 1,39 1,4399 1,42 1,41
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
16/5/202413:30PRNUSCarisma Therapeutics Announces First Patient Dosed in Phase..
09/5/202413:52EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202413:41EDGAR2Form 8-K - Current report
09/5/202413:30PRNUSCarisma Therapeutics Reports First Quarter 2024 Financial..
08/5/202417:45BWCarmila: Withdrawal of funds for the liquidity contract
08/5/202413:30PRNUSCarisma Therapeutics Presents Preclinical Proof of Concept..
07/5/202417:45BWCARMILA: Information Concerning the Total Number of Voting..
06/5/202413:30PRNUSCarisma Therapeutics to Participate in The Citizens JMP Life..
02/5/202413:30PRNUSCarisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief..
24/4/202423:05PRNUSCarisma Therapeutics Announces Upcoming Presentation at the..
24/4/202418:43BWCarmila : Lancement d’un programme de rachat d’actions pour..
22/4/202422:35PRNUSCarisma Therapeutics to Present New Data at the American..
17/4/202417:45BWCarmila: First-quarter 2024 Financial Information
05/4/202417:45BWCarmila : Informations relatives au nombre total de droits..
03/4/202413:00PRNUSCarisma Therapeutics to Present at Upcoming Conferences
01/4/202414:35PRNUSCarisma Therapeutics Provides Business Update and Reports..
01/4/202413:00PRNUSCarisma Therapeutics Announces Changes to its Board of..
21/3/202422:00PRNUSCarisma Announces Upcoming Presentations at the American..
15/3/202417:45BWCarmila: Filing of the 2023 Universal Registration Document
08/3/202417:45BWCORRIGE ET REMPLACE : Carmila : Evolution de la composition..
07/3/202422:05EDGAR2Form SC 13D/A - General statement of acquisition of..
07/3/202419:13BWCARMILA: Changes in the composition of the Board of..
04/3/202417:45BWCarmila : Informations relatives au nombre total de droits..
28/2/202413:30PRNUSCarisma Therapeutics to Participate in TD Cowen's 44th..
13/2/202417:45BWCarmila: 2023 Annual Results
02/2/202422:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202419:06EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
02/2/202417:45BWCARMILA: Information Concerning the Total Number of Voting..
16/1/202417:45BWCarmila: Resources Devoted to the Liquidity Contract as of..
08/1/202417:57BWCARMILA: Information Concerning the Total Number of Voting..
21/12/202313:00PRNUSCarisma Therapeutics to Present at the 42nd Annual J.P...
14/12/202313:00PRNUSFirst In Vivo CAR-M Lead Candidate Nominated Under..
05/12/202317:45BWCarmila : Informations relatives au nombre total de droits..
28/11/202313:00PRNUSCarisma Therapeutics Announces FDA Clearance of IND..
22/11/202313:30PRNUSCarisma Therapeutics to Participate in Evercore ISI..
10/11/202320:17BWCarmila: Termination of Liquidity Contract With BNP Paribas..
09/11/202317:45BWCARMILA : Informations relatives au nombre total de droits..
09/11/202314:36EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202313:42EDGAR2Form 8-K - Current report
09/11/202313:30PRNUSCarisma Therapeutics Reports Third Quarter 2023 Financial..
31/10/202314:25PRNUSCarisma Presents Pre-Clinical Proof of Concept for in vivo..
25/10/202315:11PRNUSCarisma to Present First Results From in vivo CAR-M..
20/10/202317:47BWCarmila: Financial Information as of 30 September 2023
02/10/202318:35BWCarmila : Emission d’un emprunt obligataire de 500 millions..
02/10/202317:45BWCARMILA : Informations relatives au nombre total de droits..
05/9/202314:30PRNUSCarisma Therapeutics to Present at Upcoming Investor..
01/9/202317:45BWCARMILA : Informations relatives au nombre total de droits..
01/9/202315:05EDGAR2Form 8-K - Current report
01/9/202314:30PRNUSCarisma Announces Latest Data from Phase 1 Clinical Trial of..
24/8/202314:30PRNUSCarisma Therapeutics to Present at Upcoming Healthcare..

Dernières Valeurs Consultées

NASDAQ
CARM
Carisma Therapeutics
TSXV
AEMC
Alaska Energy Metals
CREX
WIXBTC
Wixlar
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés